Protein-based therapeutics have led to new paradigms in disease treatment. Projected to be
half of the top ten selling drugs in 2023, proteins have emerged as rivaling and, in some …

Serum albumin physically interacts with fatty acids, small molecules, metal ions, and several
other proteins. Binding with a plethora of bioactive substances makes it a critical transport …

Peptides and proteins are widely used to treat a range of medical conditions; however, they
often have to be injected and their effects are short-lived. These shortcomings of the native …

Beyond potency, a good developability profile is a key attribute of a biological drug.
Selecting and screening for such attributes early in the drug development process can save …

Biomimetic nanoparticles have recently emerged as a novel drug delivery platform to
improve drug biocompatibility and specificity at the desired disease site, especially the …

Abstract Background & Aims Numerous studies have evaluated the role of human albumin
(HA) in managing various liver cirrhosis-related complications. However, their conclusions …

The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic
require further improvement. Currently, the development and application of novel antibody …

Oral delivery of biopharmaceuticals, as insulin, is hampered by rapid degradation and
inefficient absorption in the gastrointestinal tract (GIT). To solve this, a new class of …

Needle-free uptake across mucosal barriers is a preferred route for delivery of biologics, but
the efficiency of unassisted transmucosal transport is poor. To make administration and …

The posttranslational modifications (PTM) of human serum albumin (HSA) can result in the
development of isoforms that have been identified as potential biomarkers for advanced …